Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7493619 | 1.00 | PDE4D (0.34) | PDE4DOPRM1OPRL1CTSLCTSB | |
| SCHEMBL6575559 | 0.89 | PDE4D (0.39) | PDE4DOPRM1OPRL1CTSLCTSB | |
| SCHEMBL14107808 | 0.84 | CTSL (0.37) | PDE4DOPRM1OPRL1CTSLCTSB | |
| SCHEMBL4893196 | 0.84 | CTSL (0.37) | PDE4DOPRM1OPRL1CTSLCTSB | |
| SCHEMBL4919336 | 0.83 | TOP2A (0.31) | TOP2A | |
| SCHEMBL4919332 | 0.83 | TOP2A (0.31) | TOP2A | |
| SCHEMBL724384 | 0.79 | NAAA (0.41) | OPRM1OPRL1CTSLCTSBCTSK | |
| SCHEMBL4895151 | 0.78 | CTSL (0.36) | OPRM1OPRL1CTSLCTSBCTSK | |
| SCHEMBL14107809 | 0.78 | CTSL (0.36) | OPRM1OPRL1CTSLCTSBCTSK | |
| SCHEMBL22906947 | 0.77 | CTSL (0.41) | OPRM1OPRL1CTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176813-A1 | CARBOCYCLIC NUCLEOSIDES AND PROCESS FOR OBTAINING SUCH | STICHTING REGA VZW (BE) | 2008-07-24 | — | — | US | disclosed |
| EP-1210347-B1 | CARBOCYCLIC NUCLEOSIDES AND PROCESS FOR OBTAINING SUCH | STICHTING REGA V Z W (BE) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176813-A1 | CARBOCYCLIC NUCLEOSIDES AND PROCESS FOR OBTAINING SUCH | ATIC, ADORA2A, ADORA3 | PDE4D 2097/4885OPRM1 401/4885OPRL1 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.